ICPT Intercept Pharmaceuticals Inc.

107.48
-12.3  -10%
Previous Close 119.78
Open 120
Price To Book 26.94
Market Cap 3,518,190,884
Shares 32,733,447
Volume 2,350,174
Short Ratio
Av. Daily Volume 551,483
Stock charts supplied by TradingView

NewsSee all news

  1. Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  2. Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer

    NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  3. FDA Accepts Intercept's NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review

    NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  4. New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH

    Treatment with OCA resulted in early and sustained improvements of commercially available noninvasive biomarker and imaging assessments of fibrosis Additional patient-reported outcomes data demonstrate that pruritus in

  5. Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    Worldwide Ocaliva net sales of $61.5 million in the third quarter of 2019 representing 32% growth versus the prior year quarter; increasing full year 2019 worldwide Ocaliva net sales guidance range to between $245

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 enrolment to be completed in 2019.
Ocaliva - Obeticholic acid (OCA) - REVERSE
NASH patients with compensated cirrhosis
Phase 2 primary endpoint met - July 31, 2017. One patient death noted but DSMB noted unlikely to be related to OCA (company unsure).
Obeticholic acid (OCA) - CONTROL
NASH patients taking statins
Approved May 27 2016. Updated U.S. label for Ocaliva anticipated by early 2018
Obeticholic acid (Ocaliva)
Primary biliary cirrhosis (PBC) - POISE
PDUFA date under priority review March 26, 2020. Advisory Committee meeting expected.
Ocaliva (Obeticholic acid (OCA)) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 2 data released July 31, 2017 - primary endpoint met. Late breaker at AASLD October 23, 2017.
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)

Latest News

  1. Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  2. Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer

    NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  3. FDA Accepts Intercept's NDA for OCA for the Treatment of Liver Fibrosis Due to NASH and Grants Priority Review

    NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  4. New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH

    Treatment with OCA resulted in early and sustained improvements of commercially available noninvasive biomarker and imaging assessments of fibrosis Additional patient-reported outcomes data demonstrate that pruritus in

  5. Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    Worldwide Ocaliva net sales of $61.5 million in the third quarter of 2019 representing 32% growth versus the prior year quarter; increasing full year 2019 worldwide Ocaliva net sales guidance range to between $245

  6. Intercept Submits New Drug Application to the U.S. FDA for Obeticholic Acid in Patients with Fibrosis Due to NASH

    NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  7. Intercept to Present at Upcoming Investor Conference in October

    NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive

  8. Intercept Launches NASHTRUTH.com, an Online Educational Resource for People with Advanced Fibrosis Due to NASH

    New NASH survey available on NASHTRUTH.com reveals that 6 out of 10 NASH patients say there is not enough information about the disease available to them  NASHTRUTH.com provides people living with NASH with

  9. Intercept Appoints Lisa DeFrancesco as Vice President, Investor Relations

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive